NeoGenomics, Inc. NEO R2K

Q: What is the current share price of NeoGenomics, Inc. (NEO)?

As of 2026-07-14 21:23 PDT, NeoGenomics, Inc. (NEO) trades at $14.23 on NasdaqCM. Its 52-week range is $4.84 to $15.16.

Q: What is the market capitalisation of NEO?

NeoGenomics, Inc. (NEO) has a market capitalisation of $1.85B on NasdaqCM.

Q: What is the P/E ratio of NEO?

NEO trades at a trailing price-to-earnings (P/E) ratio of -18.48. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.72.

Q: What is the return on equity (ROE) of NEO?

NEO has a return on equity (ROE) of -11.56%. Its return on capital employed (ROCE) is -9.11%.

Q: Is NEO a good stock to buy?

This page provides a data-driven analysis of NeoGenomics, Inc. (NEO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Diagnostics & Research · United States

https://www.neogenomics.com

Company Profile ↓

$14.23

+98.19% 1Y

Mkt Cap$1.85B

P/E-18.48

P/B1.72

52W High$15.16

52W Low$4.84

Book Value$6.49

EPS (TTM)$-0.77

Company Overview

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 46.7% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $727.33M (+10.1% YoY); net profit $-108.03M.
Trailing 12 Months Year-on-year growth — revenue +11.1%.
5-Year Trend Long-term compounding — revenue CAGR 46.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	46.68%
1 Year:	11.10%

Stock Price Performance

1 Year:	+98.19%
6 Months:	+8.13%
3 Months:	+77.88%
1 Month:	+24.06%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 91% of range

$4.84 $15.16

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
Golden Cross8d ago
RSI (14)64.28 · Neutral

Price Performance

1M+24.06%

3M+77.88%

6M+8.13%

1Y+98.19%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 46.7% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-18.48

Industry PE

25.41

Forward P/E

39.03

PEG Ratio

2.09

Book Value

$6.49

Price to Book

1.72

P/S

1.95

EV/EBITDA

401.75

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

46.68%

Profit 5Y

Revenue (YoY)

11.10%

Earnings (YoY)

Profitability & Returns

ROCE

-9.11%

ROE

-11.56%

ROA

-2.64%

Profit Margin

-13.30%

Op Margin

-9.34%

Gross Margin

43.10%

EPS (Latest Qtr)

$-0.07

EPS (TTM)

$-0.77

Balance Sheet & Liquidity

Debt/Equity

0.49

Quick Ratio

3.71

Current Ratio

4.42

Debt

$408.53M

Total Assets

$1.35B

Current Assets

Working Capital

Ownership

Promoter Holding

2.05%

Chg in Prom Hold

-0.01%

FII / Inst Holding

108.24%

Chg in FII Hold

-0.14%

Financial Snapshot

Enterprise Value

$1.85B

Total Revenue (TTM)

$745.97M

EBITDA

$4.27M

Free Cash Flow

$33.17M

Operating Cash Flow

$22.42M

Shares Outstanding

130.21M

Gross Margin

43.10%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	NEO NeoGenomics, Inc. R2K	14.23	-18.48	$1.85B	0.00%	-9.11%	-11.56%	46.68%	-
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	57.43M	62.26M	-	-	63.42M	67.75M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	11.47M	9.54M	10.81M	11.17M	12.23M	27.17M	28.61M	27.34M	27.26M	22.95M	27.35M	24.89M	26.76M	27.30M	30.53M	32.32M	37.11M	47.12M	48.97M	50.83M	49.92M	46.37M	28.01M	54.06M	41.57M	52.99M	47.24M	38.23M	43.95M	48.89M	54.81M	59.89M	62.31M	65.47M	72.49M	74.88M	73.25M	77.26M	80.45M	80.86M
Operating Income	-	-561.00K	28.00K	114.00K	-	1.92M	2.19M	1.40M	-	-580.00K	1.84M	-2.06M	-	2.50M	794.00K	3.92M	-	2.55M	4.48M	3.66M	-	-5.29M	-18.91M	4.67M	-15.11M	-22.37M	-39.71M	-52.03M	-39.70M	-39.51M	-35.07M	-29.89M	-24.20M	-30.57M	-21.94M	-21.20M	-27.82M	-47.63M	-27.01M	-18.24M
Net Income	1.05M	-761.00K	-176.00K	-125.00K	-1.47M	155.00K	413.00K	-67.00K	-6.22M	-1.17M	483.00K	-4.26M	4.55M	644.00K	-380.00K	2.02M	353.00K	-2.42M	1.99M	2.14M	6.30M	-6.98M	-6.82M	2.56M	-22.11M	75.87M	-20.35M	-49.41M	-35.30M	-36.85M	-30.80M	-24.33M	-18.52M	-27.06M	-18.64M	-17.70M	-25.92M	-45.09M	-27.13M	-17.11M
Diluted EPS	0.02	-0.01	0.00	0.00	-0.03	-0.07	-0.07	-0.07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expense	-	669.00K	803.00K	871.00K	-	1.45M	1.31M	967.00K	-	862.00K	947.00K	1.27M	-	956.00K	1.07M	446.00K	-	1.21M	2.59M	2.61M	-	2.06M	2.10M	1.96M	2.46M	3.50M	7.41M	7.71M	8.63M	7.31M	7.39M	7.50M	5.29M	7.62M	7.89M	7.68M	10.18M	9.02M	8.69M	9.53M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	5.00M	5.00M	5.00M	5.00M	231.81M	240.25M	276.74M	408.83M	444.45M	484.33M	509.73M	591.64M	660.57M	727.33M
Gross Profit	15.78M	19.43M	26.84M	31.74M	40.71M	43.76M	98.10M	101.96M	127.27M	196.84M	185.89M	187.06M	187.90M	244.60M	290.10M	314.29M
Operating Income	-2.96M	-409.00K	1.21M	3.17M	2.22M	-5.63M	2.15M	2.90M	10.04M	13.01M	-13.99M	-118.75M	-157.62M	-107.74M	-92.11M	-115.88M
Net Income	-3.30M	-1.18M	65.00K	2.03M	1.13M	-2.54M	-6.14M	-396.00K	2.64M	8.01M	4.17M	-8.35M	-144.25M	-87.97M	-78.73M	-108.03M
Diluted EPS	-	-0.03	0.00	0.04	0.02	-0.04	-	-	-	-	-	-	-	-	-	-
R&D Expense	-	543.00K	2.28M	2.44M	2.69M	4.20M	4.65M	3.64M	3.00M	8.49M	8.23M	21.87M	30.33M	27.31M	31.16M	37.08M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	13.65M	19.95M	30.07M	39.92M	81.11M	351.29M	337.12M	344.45M	505.01M	709.51M	988.33M	1.87B	1.74B	1.68B	1.64B	1.36B
Total Equity	5.64M	3.13M	5.90M	9.22M	21.71M	60.41M	208.52M	162.32M	171.96M	320.44M	507.41M	694.29M	1.11B	998.02M	941.54M	902.34M	836.56M
Cash & Equivalents	1.63M	1.10M	2.63M	1.87M	4.83M	33.69M	23.42M	12.53M	12.82M	9.81M	173.02M	228.71M	316.83M	263.18M	342.49M	367.01M	159.62M
Long Term Debt	-	-	-	-	-	-	52.25M	91.95M	91.13M	92.88M	-	-	-	-	538.20M	340.33M	341.86M
Total Liabilities	-	10.52M	14.05M	20.86M	18.20M	20.70M	113.17M	150.52M	139.88M	184.57M	202.10M	294.04M	761.50M	742.01M	739.69M	735.70M	523.27M
Current Liabilities	-	9.17M	11.44M	17.76M	14.32M	14.62M	40.06M	38.11M	36.47M	60.92M	63.90M	73.18M	87.23M	89.93M	96.30M	301.24M	88.30M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-2.05M	69.00K	-492.00K	2.23M	-	-	-	18.04M	44.79M	23.37M	1.46M	-26.72M	-65.99M	-1.95M	7.02M	5.23M
Investing Cash Flow	-916.00K	-897.00K	-3.65M	-2.01M	-	-	-	-13.69M	-139.69M	-19.63M	-159.44M	-632.37M	517.00K	76.71M	12.86M	-12.34M
Financing Cash Flow	2.43M	2.36M	3.38M	2.75M	-	-	-	-4.09M	91.96M	159.47M	235.60M	725.28M	11.83M	4.55M	4.65M	-200.29M
Capital Expenditure	-916.00K	-897.00K	-2.62M	-2.01M	-3.77M	-2.21M	-7.54M	-13.69M	-14.31M	-20.03M	-29.10M	-64.14M	-30.89M	-28.75M	-41.06M	-27.01M
Free Cash Flow	-2.97M	-828.00K	-3.11M	216.00K	-	-	-	4.35M	30.48M	3.34M	-27.64M	-90.86M	-96.88M	-30.70M	-34.04M	-21.78M

Ratios (Annual)

Figures in %.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	536.7%	634.7%	814.3%	875.1%	42.3%	42.4%	46.0%	48.1%	41.8%	38.6%	36.9%	41.3%	43.9%	43.2%
Operating Margin %	-	-	24.2%	63.5%	44.4%	-112.7%	0.9%	1.2%	3.6%	3.2%	-3.1%	-24.5%	-30.9%	-18.2%	-13.9%	-15.9%
Net Margin %	-	-	1.3%	40.7%	22.6%	-50.7%	-2.6%	-0.2%	1.0%	2.0%	0.9%	-1.7%	-28.3%	-14.9%	-11.9%	-14.9%
ROE %	-105.4%	-20.0%	0.7%	9.4%	1.9%	-1.2%	-3.8%	-0.2%	0.8%	1.6%	0.6%	-0.8%	-14.5%	-9.3%	-8.7%	-12.9%
ROCE %	-66.1%	-4.8%	9.8%	12.4%	3.3%	-1.8%	0.7%	0.9%	2.3%	2.0%	-1.5%	-6.7%	-9.6%	-6.8%	-6.9%	-9.1%

Shareholding Pattern

Insiders

2.05%

Institutions

108.24%

Public Float

110.52%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	15.33%	19.96M	$308.84M
2	First Light Asset Management, LLC	7.47%	9.73M	$150.57M
3	Greenhouse Funds, LLLP	6.99%	9.10M	$140.82M
4	Vanguard Portfolio Management LLC	5.85%	7.62M	$117.95M
5	First Trust Advisors LP	4.73%	6.16M	$95.36M
6	Vanguard Capital Management LLC	4.34%	5.66M	$87.52M
7	Braidwell LP	4.31%	5.62M	$86.93M
8	State Street Corporation	3.93%	5.12M	$79.23M
9	Shaw D.E. & Co., Inc.	3.20%	4.16M	$64.44M
10	Schroder Investment Management Group	2.74%	3.57M	$55.22M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NEO

Google News Fri, 19 Jun 2026

NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxNQnpsNTBNRnJIc2FQTDhLeFNTMDJyYkk5MGRkdGVYOXBoR3A1Umh3eFlwRUJZZ3VHTXlsNjQ5ZFlLZWdjTzZhM0NJVEw3SjFVdEl4Qm9QSGQtUkdzRk9GRVpaZDk5b0xpQlRVbDVmRmFscmhIaTV4cG1saEJXM3Ezd3JNZ1FGTW1VMnJWeG…

Google News hu, 09 Jul 2026

NeoGenomics (NEO) Stock Trades Up, Here Is Why - StockStory

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOZ1RCT3FDZXU0Qy1LcmFqZ0dQQkJoT3hRTWpoOURnMVI3XzNiTWk0MWM5eTFYbzlsTXRnRjFieXlBS1dELUlILUVCTUlyVHVhRC0xVE51OGlaUmJBRmZLYTRnVENoNzllbFUxWVVTb3hoV2x1QUhRRWp6RHgxR20xcE5KZnowTkdEUFkzen…

Google News Mon, 13 Jul 2026

NeoGenomics, Inc. Stock 12‑Month Price Target Raised to $15.67, Implies 11% Upside - TradingView

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxPX0YxVmx3MVhRUmVmNEJzbUhOZHo3MlQwbUt4ak9GR2RoWTNYNVM3eFA3NjRDNXpJbmR5UmhiQUxVdXlSdHZzVUt2NXBEVE9JSmYzM01SMS1jeFZRY05hX25kemtiWWtQVWxySXIyb0VhSFZnaW41NFc1bGluWmZFZUNYSGRCc1VjYVJuZk…

Google News ue, 14 Jul 2026

Does NeoGenomics (NEO) New PTEN CDx Move Reveal a Deeper Precision Oncology Strategy Shift? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNX1Bwdkh1OUQ2LWwzekNsRzA5T2wyemZzUjFRZVRJaXhBQ3RKU0F6aUNlaGtFQkVEY294MlJFUHVsTTgteGhiY0xXMEE3VGlENW8tamI1ZDJLRHZPRVl3eHFqdGU1REltZmdpRHFzUG9nNW5ocWgzTHkweElfTUZibnVDd3YyQW5IYk82cT…

Google News Mon, 13 Jul 2026

Applied Digital vs. TeraWulf: Which Neocloud Stock Is the Better Buy? - The Motley Fool

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOVkhGeGZ6ZEU1X3dzVlNlT200TUllZ3dpOGMwaTR6Zk9WcWpsanFjWlNjd0Z5X2dadUxJY3VzVFRHZHY3WjJteUZVc1FZcEF1N0dqZzNqNW9yWi10YXVaYjBYM0xDTTZvTzNKWVc2bFhZT0NXR1pfOHBEVUxjMUZNX3k5eHZFTlBrVjJyRl…

Google News Fri, 10 Jul 2026

NeoGenomics Inc (NEO) Shares Fall 4.2% -- What GF Score of 72 Te - GuruFocus

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxOVXVEWXN3ekhVQThOclRkRjlzaHZ0MVpZZENDZHZsanF3WVM2TDBqS3FUTUhiWEU5d0FUeC1fS3pRUl9abGZHdmxKaFFaQ09iVVFLSUdtMldaRnVLdVJ6TDFkNVRzVGVpczd5bzQ2Sk5VRVFEbEY1R2FaYjhsVllQSkJiMVNKbVlLRGhHY3…

NEO — Frequently Asked Questions

What is the current share price of NeoGenomics, Inc. (NEO)?

As of 2026-07-14 21:23 PDT, NeoGenomics, Inc. (NEO) trades at $14.23 on NasdaqCM. Its 52-week range is $4.84 to $15.16.

What is the market capitalisation of NEO?

NeoGenomics, Inc. (NEO) has a market capitalisation of $1.85B on NasdaqCM.

What is the P/E ratio of NEO?

NEO trades at a trailing price-to-earnings (P/E) ratio of -18.48. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.72.

What is the return on equity (ROE) of NEO?

NEO has a return on equity (ROE) of -11.56%. Its return on capital employed (ROCE) is -9.11%.

Is NEO a good stock to buy?

This page provides a data-driven analysis of NeoGenomics, Inc. (NEO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

NeoGenomics, Inc. NEO R2K

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock? - Yahoo Finance

NeoGenomics (NEO) Stock Trades Up, Here Is Why - StockStory

NeoGenomics, Inc. Stock 12‑Month Price Target Raised to $15.67, Implies 11% Upside - TradingView

Does NeoGenomics (NEO) New PTEN CDx Move Reveal a Deeper Precision Oncology Strategy Shift? - simplywall.st

Applied Digital vs. TeraWulf: Which Neocloud Stock Is the Better Buy? - The Motley Fool

NeoGenomics Inc (NEO) Shares Fall 4.2% -- What GF Score of 72 Te - GuruFocus

NEO — Frequently Asked Questions

What is the current share price of NeoGenomics, Inc. (NEO)?

What is the market capitalisation of NEO?

What is the P/E ratio of NEO?

What is the return on equity (ROE) of NEO?

Is NEO a good stock to buy?

Explore More